A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen - Kalimuddin, Shirin; Wijaya, Limin; Chan, Yvonne F.Z.; Wong, Abigail W.L.; Oh, Helen M.L.; Wang, Lin-Fa; Kassim, Julaihabee A.; Zhao, Jing; Shi, Zhongkai; Low, Jenny G. (Vaccine, 2017)
Keywords: Adjuvants; Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - chemistry; Adult; Adults; Aged; agonists; Animals; Antibodies; Antibodies, Neutralizing - biosynthesis; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Antigens; Cercopithecus aethiops; Disease; disease control; Drug-Related Side Effects and Adverse Reactions; Female; geometry; Healthy Volunteers; Humans; immune response; Immunogenicity; Immunogenicity, Vaccine; Influenza; Lyssavirus; Male; Middle Aged; neutralization; neutralizing antibodies; Phase II; PIKA adjuvant; Post-Exposure Prophylaxis; Prophylaxis; Rabies; Rabies - prevention & control; Rabies lyssavirus; Rabies vaccine; Rabies Vaccines - administration & dosage; Rabies Vaccines - adverse effects; Rabies Vaccines - immunology; Rabies virus - immunology; Randomization; Safety; TLR3; TLR3 protein; Toll-like receptor 3; Toll-Like Receptor 3 - agonists; Toll-Like Receptor 3 - immunology; Toll-like receptors; vaccine adjuvants; Vaccines; Vero Cells; Viruses; Young Adult; Southeast Asia; CSIRO; CTCAE; PIKA adjuvant; CIRB; IPRV; RVNA; FAVN; ACIP; HSA; RFFIT; Safety; eCRF; WHO; AE; CI; Phase II; PIKA; CTRU; GMP; GMT; IMU; RIG; Immunogenicity; SAE; MEdDRA; FAS; PEP; Rabies vaccine; TLR3